Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Working Capital Changes (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Working Capital Changes for 13 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes rose 141.19% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 377.41% increase, with the full-year FY2024 number at -$411000.0, down 90.28% from a year prior.
  • Other Working Capital Changes was $1.3 million for Q3 2025 at Theravance Biopharma, up from $50500.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $2.4 million in Q2 2022 to a low of -$3.9 million in Q1 2021.
  • A 5-year average of -$279250.0 and a median of -$54500.0 in 2024 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: crashed 2788.19% in 2021, then soared 141.19% in 2025.
  • Theravance Biopharma's Other Working Capital Changes stood at -$3.9 million in 2021, then skyrocketed by 41.41% to -$2.3 million in 2022, then soared by 77.16% to -$518000.0 in 2023, then increased by 12.36% to -$454000.0 in 2024, then soared by 377.31% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Working Capital Changes are $1.3 million (Q3 2025), $50500.0 (Q2 2025), and -$148000.0 (Q1 2025).